Table II.
Correlation of high PTPRG antisense RNA 1 expression with other clinical characteristics of patients with gastric cancer.
| Characteristics | n | HR 95% CI | P-value |
|---|---|---|---|
| Clinical stages | |||
| 2 | 126 | 1.7 (0.89–3.26 | 0.11 |
| 4 | 140 | 0.72 (0.46–1.11) | 0.13 |
| Pathological grades | |||
| Poorly differentiated | 121 | 1.26 (0.78–2.06) | 0.34 |
| Moderately differentiated | 67 | 0.47 (0.24–0.92) | 0.024 |
| Well differentiated | |||
| HER2 status | |||
| Positive | 202 | 1.43 (0.94–2.19) | 0.097 |
| Treatments | |||
| 5-FU based adjuvant | 34 | 1.42 (0.57–3.54) | 0.45 |
| Other adjuvants (e.g. irinotecan) | 76 | 0.52 (0.2–1.36) | 0.17 |
| T stage | |||
| 2 | 241 | 1.55 (0.99–2.44) | 0.054 |
| 4 | 38 | 0.61 (0.26–1.41) | 0.24 |
| N stage | |||
| 1 + 2 + 3 | 422 | 1.3 (0.97–1.73) | 0.074 |
| 2 | 121 | 0.71 (0.45–1.11) | 0.13 |
| 3 | 76 | 1.31 (0.76–2.26) | 0.33 |
| M stage | |||
| M1 | 56 | 0.63 (0.33–1.22) | 0.17 |
| Lauren classification | |||
| Intestinal | 269 | 1.47 (0.97–2.23) | 0.067 |
| Mixed | 29 | 1.56 (0.5 −4.77) | 0.43 |
| Diffuse | 240 | 1.35 (0.96–1.9) | 0.084 |
CI, confidence interval; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; 5-FU, 5-fluorouracil.